A phase II randomized, double-blind, double-dummy, placebo and comparator-controlled, parallel group, multi-center study to investigate the safety and efficacy of a single dose of JNJ-17216498 administered to subjects with narcolepsy.

Trial Profile

A phase II randomized, double-blind, double-dummy, placebo and comparator-controlled, parallel group, multi-center study to investigate the safety and efficacy of a single dose of JNJ-17216498 administered to subjects with narcolepsy.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2014

At a glance

  • Drugs JNJ 17216498 (Primary) ; Modafinil
  • Indications Narcolepsy
  • Focus Therapeutic Use
  • Sponsors ALZA Corporation
  • Most Recent Events

    • 08 Apr 2009 Patient numbers amended from 64 to 65 as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Actual end date (December 2007) added as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top